To explore the clinical efficacy of Danggui Shaoyao Powder combined with low-dose low-molecular-weight heparin calcium in the treatment of early-onset severe preeclampsia.

96 patients with early-onset severe preeclampsia admitted to Shuyang Affiliated Hospital of Nanjing University of Chinese Medicine from September 2022 to September 2024 were included.96 patients with early-onset severe preeclampsia were randomly divided into an observation group and a control group, with 48 cases in each group. The control group received subcutaneous injection of low molecular weight heparin calcium, while the observation group received treatment in combination with Danggui Shaoyao Powder. After one week of treatment, the traditional Chinese medicine syndrome scores, blood pressure, vascular endothelial cell adhesion molecule-1 (VCAM-1), angiotensinⅡ (AngII), coagulation indicators [thrombin time (TT), prothrombin time (PT), plasma fibrinogen (FIB), D-dimer], proteinuria [24-hour urine protein quantification, microalbumin (mAlb), transferrin (TRF), urinary alpha 1-microglobulin (α 1-MG)], perinatal outcomes, and adverse reactions were compared between the two groups.

After treatment, the scores of dizziness, headache, blurred vision, abdominal or chest discomfort, and edema decreased in both groups (P<0.05), and the observation group was lower than the control group (P<0.05). After treatment, both groups showed prolonged PT and TT (P<0.05), with the observation group exhibiting longer durations than the control group (P<0.05). Both groups experienced a decrease in FIB and D-dimer levels (P<0.05), with the observation group showing lower levels than the control group (P<0.05). After treatment, both groups showed a decrease in diastolic blood pressure, systolic blood pressure, serum VCAM-1, serum AngII, 24-hour urinary protein quantification, mAlb, TRF, and α 1-MG (P<0.05), with the observation group being lower than the control group (P<0.05). The gestational age of delivery in the observation group was longer than that in the control group (P<0.05), and the birth weight of newborns was higher than that in the control group (P<0.05). Additionally, the incidence of fetal growth restriction, fetal distress, and neonatal asphyxia was lower in the observation group than in the control group (P<0.05).

Danggui Shaoyao Powder in the treatment of early-onset severe preeclampsia helps alleviate clinical symptoms and improve perinatal outcomes.